204 related articles for article (PubMed ID: 24173185)
1. Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy.
Nery JA; Bernardes Filho F; Quintanilha J; Machado AM; Oliveira Sde S; Sales AM
An Bras Dermatol; 2013; 88(5):787-92. PubMed ID: 24173185
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics of leprosy reactions in paucibacillary and multibacillary individuals attended at two reference centers in Recife, Pernambuco].
Teixeira MA; Silveira VM; França ER
Rev Soc Bras Med Trop; 2010; 43(3):287-92. PubMed ID: 20563498
[TBL] [Abstract][Full Text] [Related]
3. Leprosy among children under 15 years of age: literature review.
Oliveira MB; Diniz LM
An Bras Dermatol; 2016 Apr; 91(2):196-203. PubMed ID: 27192519
[TBL] [Abstract][Full Text] [Related]
4. Description of leprosy classification at baseline among patients enrolled at the uniform multidrug therapy clinical trial for leprosy patients in Brazil.
Moura RS; Penna GO; Cardoso LP; de Andrade Pontes MA; Cruz R; de Sá Gonçalves H; Fernandes Penna ML; de Araújo Stefani MM; Bührer-Sékula S
Am J Trop Med Hyg; 2015 Jun; 92(6):1280-4. PubMed ID: 25940192
[TBL] [Abstract][Full Text] [Related]
5. A multi-centre study on quality of routine data collection on relapses.
Deepak S; Gazzoli G
Lepr Rev; 2012 Dec; 83(4):340-3. PubMed ID: 23614251
[TBL] [Abstract][Full Text] [Related]
6. Leprosy beyond MDT: study of follow-up of 100 released from treatment cases.
Vara N; Agrawal M; Marfatia Y
Indian J Lepr; 2010; 82(4):189-94. PubMed ID: 21434595
[TBL] [Abstract][Full Text] [Related]
7. Leprosy: a review of laboratory and therapeutic aspects--part 2.
Lastória JC; Abreu MA
An Bras Dermatol; 2014; 89(3):389-401. PubMed ID: 24937811
[TBL] [Abstract][Full Text] [Related]
8. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
[TBL] [Abstract][Full Text] [Related]
9. Progression of leprosy disability after discharge: is multidrug therapy enough?
Sales AM; Campos DP; Hacker MA; da Costa Nery JA; Düppre NC; Rangel E; Sarno EN; Penna MLF
Trop Med Int Health; 2013 Sep; 18(9):1145-1153. PubMed ID: 23937704
[TBL] [Abstract][Full Text] [Related]
10. Observations in 11 patients with leprosy and human immunodeficiency virus co-association.
Pai VV; Tayshetye PU; Ganapati R
Indian J Dermatol Venereol Leprol; 2011; 77(6):714-6. PubMed ID: 22016284
[No Abstract] [Full Text] [Related]
11. TH17 cells, interleukin-17 and interferon-γ in patients and households contacts of leprosy with multibacillary and paucibacillary forms before and after the start of chemotherapy treatment.
de Almeida-Neto FB; Assis Costa VM; Oliveira-Filho AF; de Souza Franco E; Tavares Julião de Lima EV; Barros de Lorena VM; Oliveira de Souza VM; de Sousa Maia MB
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1354-61. PubMed ID: 25429820
[TBL] [Abstract][Full Text] [Related]
12. Type 1 reaction in leprosy: a model for a better understanding of tissue immunity under an immunopathological condition.
Andrade PR; Pinheiro RO; Sales AM; Illarramendi X; Barbosa MG; Moraes MO; Jardim MR; Nery JA; Sampaio EP; Sarno EN
Expert Rev Clin Immunol; 2015 Mar; 11(3):391-407. PubMed ID: 25666357
[TBL] [Abstract][Full Text] [Related]
13. Effect of corticosteroid usage combined with multidrug therapy on nerve damage assessed using nerve conduction studies: a prospective cohort study of 365 untreated multibacillary leprosy patients.
Capadia GD; Shetty VP; Khambati FA; Ghate SD
J Clin Neurophysiol; 2010 Feb; 27(1):38-47. PubMed ID: 20087206
[TBL] [Abstract][Full Text] [Related]
14. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
15. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.
Lazo-Porras M; Prutsky GJ; Barrionuevo P; Tapia JC; Ugarte-Gil C; Ponce OJ; Acuña-Villaorduña A; Domecq JP; De la Cruz-Luque C; Prokop LJ; Málaga G
BMC Infect Dis; 2020 Jan; 20(1):62. PubMed ID: 31959113
[TBL] [Abstract][Full Text] [Related]
16. Bilateral greater auricular nerve thickening in leprosy.
Gupta N; Vinod KS; Singh G; Nischal N
QJM; 2020 Aug; 113(8):579. PubMed ID: 31681949
[No Abstract] [Full Text] [Related]
17. Leprosy Reactions in Patients Coinfected with HIV: Clinical Aspects and Outcomes in Two Comparative Cohorts in the Amazon Region, Brazil.
Pires CA; Jucá Neto FO; de Albuquerque NC; Macedo GM; Batista Kde N; Xavier MB
PLoS Negl Trop Dis; 2015; 9(6):e0003818. PubMed ID: 26029928
[TBL] [Abstract][Full Text] [Related]
18. Type 2 leprosy reaction with Sweet's syndrome-like presentation.
Chiaratti FC; Daxbacher EL; Neumann AB; Jeunon T
An Bras Dermatol; 2016; 91(3):345-9. PubMed ID: 27438203
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design.
Penna GO; Pontes MA; Cruz R; Gonçalves Hde S; Penna ML; Bührer-Sékula S
Mem Inst Oswaldo Cruz; 2012 Dec; 107 Suppl 1():22-7. PubMed ID: 23283449
[TBL] [Abstract][Full Text] [Related]
20. Type 2 lepra reaction as a cause of pyrexia of unknown origin.
Vinod KV; Chandramohan R; Dutta TK; Rajesh NG; Basu D
J Assoc Physicians India; 2012 Apr; 60():70-2. PubMed ID: 23029751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
